Method of reducing formation of etanercept aggregates or fragments

1. A method of reducing formation of etanercept aggregates or fragments in a composition comprising combining about 50 mg/mL etanercept with about 1% (w/v) sucrose, 0.26% (w/v) to 2% (w/v) mannitol or lysine; and less than 50 mM NaCl in an aqueous pharmaceutical composition having a pH of about 6.0 to 6.6, wherein the aqueous pharmaceutical composition comprises a buffer, the composition is free of arginine and cysteine, the composition has at least 90 wt. % correctly folded etanercept, the composition has less than 1 wt. % aggregate, and wherein the combination of said sucrose and said mannitol or lysine stabilizes said etanercept in said aqueous pharmaceutical composition, wherein the composition has an osmolality from about 180 to about 420 mOsM, and wherein the etanercept is prepared by a mixed mode cation exchange chromatography and mixed mode anion exchange chromatography method resulting in less than 1 wt. % aggregate.

2. The method of claim 1 , wherein the aqueous etanercept composition has at M 3 or T 2 or T 4 no more than, on average, about 10,000 subvisible particles per mL having a size greater than 5 μm.

3. The method of claim 1 , wherein the aqueous etanercept composition elicits long term storage stability as characterized by at least one of:

SEC analysis at M 3 or T 4 at 40° C. of: monomer content greater than 90 wt. %;

aggregate content of less than 1 wt, %; and fragment 3 content less than 5 wt. %; and HIC analysis at M 3 or T 2 or T 4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than about 3 wt. %.

4. The method of claim 1 , wherein the aqueous etanercept composition is characterized by SEC analysis at M 3 or T 2 or T 4 in which: fragment 3 content is less than 10 wt %.

5. The method of claim 1 , wherein the aqueous etanercept composition elicits long term storage stability as characterized by: an HIC analysis at M 3 or T 2 or T 4 wherein the amount of the composition represented by peak 2 of the HIC chromatogram is greater than or equal to about 95 wt. %; and wherein, if peak 3 is present on the HIC chromatogram, the amount of the composition represented by peak 3 is less than or equal to about 3 wt. %.

6. The method of claim 1 , further comprising adding about 10 mM to about 200 mM of a tonicity modifier selected from potassium chloride, sodium citrate, or a combination thereof; and a citrate buffer to the composition.

7. A method of treating a patient in need of treatment with etanercept, comprising administering to said patient the aqueous pharmaceutical composition made according to the method of claim 1 , comprising injecting the aqueous pharmaceutical composition subcutaneously or intramuscularly.

8. The method of claim 7 , comprising administering 25-100 mg etanercept per dose to the subject.

9. A method of treating a subject in need thereof for rheumatoid arthritis, psoriatic arthritis psoriatic arthritis, ankylosing spondylitis, Wegener's disease, Crohn's disease, chronic obstructive pulmonary disease (COPD), Hepatitis C, endometriosis, asthma, cachexia, psoriasis, or atopic dermatitis comprising administering to the subject the aqueous pharmaceutical composition made according to the method of claim 1 .

10. The method of claim 9 , comprising administering 25-100 mg etanercept per dose to the subject.

11. The method of claim 9 , wherein the administering comprises injecting the aqueous etanercept composition subcutaneously or intramuscularly.

12. The method of claim 1 , wherein the etanercept is 50 mg/mL.

13. The method of claim 1 , wherein the sucrose is 1% (w/v).

14. The method of claim 7 , wherein the etanercept is 50 mg/mL.

15. The method of claim 7 , wherein the sucrose is 1% (w/v).

16. The method of claim 9 , wherein the etanercept is 50 mg/mL.

17. The method of claim 9 , wherein the sucrose is 1% (w/v).